

Resource Summary Report

Generated by [dkNET](#) on Aug 8, 2026

Ms CD3 MolCpx BUV496 17A2 50ug

RRID:AB_2870707

Type: Antibody

Proper Citation

BD Biosciences Cat# 741117, RRID:AB_2870707

Antibody Information

URL: http://antibodyregistry.org/AB_2870707

Proper Citation: BD Biosciences Cat# 741117, RRID:AB_2870707

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Ms CD3 MolCpx BUV496 17A2 50ug

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: 17A2

Antibody ID: AB_2870707

Vendor: BD Biosciences

Catalog Number: 741117

Record Creation Time: 20250820T062854+0000

Record Last Update: 20250821T001403+0000

Ratings and Alerts

No rating or validation information has been found for Ms CD3 MolCpx BUV496 17A2 50ug.

No alerts have been found for Ms CD3 MolCpx BUV496 17A2 50ug.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Cheng BY, et al. (2026) Pharmacologic glycoengineering of Fc γ receptor IIIa enhances force-resistant IgG-Fc γ R interactions and anti-tumor antibody efficacy. *Immunity*, 59(7), 2030.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Broderick C, et al. (2025) A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma. *Cancer discovery*, 15(8), 1717.

Benmebarek MR, et al. (2025) Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME. *Immunity*, 58(4), 926.